Wintest
6721
Osaka Yuka Industry
4124
D. Western Therapeutics Institute
4576
Asiro
7378
Hamee
3134
(Q1)Jun 30, 2024 | (FY)Mar 31, 2024 | (Q4)Mar 31, 2024 | (Q3)Dec 31, 2023 | (Q2)Sep 30, 2023 | (Q1)Jun 30, 2023 | (FY)Mar 31, 2023 | (Q4)Mar 31, 2023 | (Q3)Dec 31, 2022 | (Q2)Sep 30, 2022 | |
---|---|---|---|---|---|---|---|---|---|---|
Total revenue | 24.32%53.59B | 11.23%208.33B | 24.75%48.08B | 7.45%64.17B | 7.06%52.98B | 8.98%43.1B | 13.21%187.3B | 12.56%38.54B | 10.20%59.73B | 17.94%49.48B |
Cost of revenue | 25.32%32.72B | 7.32%123.37B | 18.49%29.13B | 2.50%36.22B | 4.41%31.92B | 6.72%26.11B | 16.29%114.95B | 13.10%24.58B | 13.46%35.33B | 21.87%30.57B |
Gross profit | 22.79%20.87B | 17.43%84.96B | 35.78%18.95B | 14.62%27.96B | 11.33%21.06B | 12.64%16.99B | 8.62%72.35B | 11.62%13.96B | 5.78%24.39B | 12.11%18.92B |
Operating expense | 15.33%16.71B | 11.67%66.14B | 25.27%17.4B | 7.81%18.7B | 6.74%15.55B | 7.94%14.49B | 9.16%59.23B | 2.34%13.89B | 11.36%17.35B | 11.34%14.57B |
Operating profit | 65.86%4.16B | 43.45%18.82B | 2,214.93%1.55B | 31.41%9.25B | 26.74%5.51B | 50.57%2.51B | 6.27%13.12B | 106.27%67M | -5.83%7.04B | 14.76%4.35B |
Net non-operating interest income (expenses) | 63.86%-30M | 37.41%-261M | 121.50%23M | 81.16%-26M | -57.66%-175M | -36.07%-83M | -51.09%-417M | -48.61%-107M | -137.93%-138M | -56.34%-111M |
Non-operating interest income | -48.95%73M | 120.51%430M | 30.86%106M | 95.83%94M | 180.65%87M | 308.57%143M | 248.21%195M | 912.50%81M | 166.67%48M | 287.50%31M |
Non-operating interest expense | -54.42%103M | 12.91%691M | -55.85%83M | -35.48%120M | 84.51%262M | 135.42%226M | 84.34%612M | 135.00%188M | 144.74%186M | 79.75%142M |
Net investment income | -389.25%-455M | 5.81%-648M | -110.07%-313M | -94.86%22M | 62.07%-264M | 65.68%-93M | -319.11%-688M | -175.63%-149M | 181.58%428M | -1,264.71%-696M |
Gain(Loss) on financial instruments designated as cash flow hedges | ||||||||||
Gain(Loss) on derecognition of available-for-sale financial assets | ||||||||||
Income from associates and other participating interests | ||||||||||
Special income (charges) | -150.00%-10M | -411.85%-2.94B | 81.67%-99M | -5,386.54%-2.85B | -64.00%18M | 87.50%-4M | -151.95%-574M | -705.97%-540M | 83.12%-52M | 126.04%50M |
Less:Restructuring and mergern&acquisition | ---- | 44.22%212M | -52.75%43M | ---- | ---- | ---- | --147M | --91M | ---- | ---- |
Less:Other special charges | 150.00%10M | -100.24%-1M | -99.77%1M | 400.00%12M | 64.71%-18M | -87.50%4M | 121.74%412M | 10,775.00%435M | 98.08%-4M | -168.42%-51M |
Less:Write off | ---- | 18,080.00%2.73B | 292.86%55M | --2.67B | ---- | ---- | -98.10%15M | -77.78%14M | --0 | ---- |
Other non-operating income (expenses) | -1,200.00%-11M | -150.00%-102M | -113.75%-33M | 45.76%-32M | -300.00%-38M | -75.00%1M | -27.92%204M | 336.36%240M | -243.90%-59M | -85.71%19M |
Income before tax | 56.85%3.65B | 27.72%14.87B | 330.82%1.13B | -11.87%6.36B | 39.88%5.05B | 78.59%2.33B | -15.47%11.64B | 48.58%-490M | -1.14%7.22B | 0.08%3.61B |
Income tax | 119.39%1.14B | 52.07%5.06B | 153.65%360M | 28.89%2.94B | 7.73%1.24B | -8.11%521M | -28.55%3.33B | -299.40%-671M | -14.05%2.28B | -15.74%1.15B |
Net income | 38.89%2.51B | 17.97%9.81B | 324.18%772M | -30.71%3.42B | 54.99%3.81B | 145.58%1.81B | -8.78%8.31B | 123.21%182M | 6.24%4.94B | 9.74%2.46B |
Net income continuous operations | 38.82%2.51B | 17.97%9.81B | 325.97%771M | -30.69%3.42B | 54.95%3.81B | 145.38%1.81B | -8.78%8.31B | 123.06%181M | 6.24%4.94B | 9.74%2.46B |
Noncontrolling interests | ||||||||||
Net income attributable to the company | 38.89%2.51B | 17.97%9.81B | 324.18%772M | -30.71%3.42B | 54.99%3.81B | 145.58%1.81B | -8.78%8.31B | 123.21%182M | 6.24%4.94B | 9.74%2.46B |
Preferred stock dividends | ||||||||||
Other under preferred stock dividend | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Net income attributable to common stockholders | 38.89%2.51B | 17.97%9.81B | 324.18%772M | -30.71%3.42B | 54.99%3.81B | 145.58%1.81B | -8.78%8.31B | 123.21%182M | 6.24%4.94B | 9.74%2.46B |
Gross dividend payment | ||||||||||
Basic earnings per share | 41.18%27.84 | 18.83%107.73 | 336.22%8.55 | -30.11%37.63 | 55.97%41.83 | 145.27%19.72 | -7.71%90.66 | 123.76%1.96 | 7.32%53.84 | 11.15%26.82 |
Diluted earnings per share | 41.27%27.83 | 18.83%107.65 | 336.22%8.55 | -30.09%37.61 | 55.90%41.78 | 145.33%19.7 | -7.72%90.59 | 123.76%1.96 | 7.30%53.8 | 11.16%26.8 |
Dividend per share | 0 | 29.23%42 | 63.33%24.5 | 0 | 0.00%17.5 | 0 | 0.00%32.5 | -33.33%15 | 0 | 75.00%17.5 |
Currency Unit | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY | JPY |
Accounting Standards | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP | NonUS-GAAP |